Clinical Trial

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib and obinutuzumab may kill more cancer cells.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-05-07; most recent amendment 2026-02-05.
Status change: Not Yet Recruiting → Recruiting 2021-12-07
Trial Details
NCT Number NCT04883437
Lead Sponsor Emory University
Collaborators: AstraZeneca, National Cancer Institute (NCI)
Conditions Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Enrollment 49 participants
Start Date 2021-09-03
Primary Completion 2026-09-23 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-09